Medication Discontinuation in the IMPROVE-IT Trial
暂无分享,去创建一个
R. Califf | R. Giugliano | E. Braunwald | L. Newby | C. Cannon | M. Roe | Y. Lokhnygina | A. Navar | M. Blazing | A. Tershakovec | Jennifer A. White
[1] Rabia Khan,et al. Investing in medication adherence improves health outcomes and health system efficiency , 2018, OECD Health Working Papers.
[2] I. Wilson,et al. ESPACOMP Medication Adherence Reporting Guideline (EMERGE) , 2018, Annals of Internal Medicine.
[3] S. Yusuf,et al. Interpreting Geographic Variations in Results of Randomized, Controlled Trials. , 2016, The New England journal of medicine.
[4] B. Lewis,et al. On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). , 2016, American heart journal.
[5] J. Hippisley-Cox,et al. Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database , 2016, British Medical Journal.
[6] S. Halvorsen,et al. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction , 2016, BMC Cardiovascular Disorders.
[7] B. Nordestgaard,et al. Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study. , 2016, European heart journal.
[8] T. Henry,et al. Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. , 2015, American heart journal.
[9] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[10] Akshay S. Desai,et al. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.
[11] R. Califf,et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[12] H. Krumholz,et al. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010. , 2014, JAMA internal medicine.
[13] Jennifer G. Robinson,et al. Racial/Ethnic and Gender Gaps in the Use of and Adherence to Evidence-Based Preventive Therapies Among Elderly Medicare Part D Beneficiaries After Acute Myocardial Infarction , 2014, Circulation.
[14] J. Spertus,et al. Beyond medication prescription as performance measures: optimal secondary prevention medication dosing after acute myocardial infarction. , 2013, Journal of the American College of Cardiology.
[15] J. Dallongeville,et al. Discontinuation of statin therapy due to muscular side effects: a survey in real life. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[16] Matthew K Ito,et al. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. , 2013, Journal of clinical lipidology.
[17] T. Brennan,et al. Warnings Without Guidance: Patient Responses to an FDA Warning About Ezetimibe , 2012, Medical care.
[18] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[19] R. Califf,et al. An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. , 2010, American heart journal.
[20] Michael Miller,et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. , 2009, The New England journal of medicine.
[21] N. Toma. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis , 2009 .
[22] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[23] R. Califf,et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. , 2008, American heart journal.
[24] J. Chambers,et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.
[25] A. Zwinderman,et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.
[26] M. Mitka. Cholesterol drug controversy continues. , 2008, JAMA.
[27] Harlan M Krumholz,et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. , 2006, Archives of internal medicine.
[28] M. Pfeffer,et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.
[29] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[30] A. Fendrick,et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations , 2004, Journal of General Internal Medicine.
[31] R. Platt,et al. Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings? , 1995, The New England journal of medicine.